{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:49:38Z","timestamp":1792198178826,"version":"4.4.0"},"reference-count":154,"publisher":"Tsinghua University Press","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.26599\/1671-5411.2024.06.003","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T08:41:41Z","timestamp":1720514501000},"page":"669-681","source":"Crossref","is-referenced-by-count":19,"title":["The impact of female sex hormones on cardiovascular disease: from mechanisms to hormone therapy"],"prefix":"10.26599","volume":"21","author":[{"given":"Yi","family":"KAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lu","family":"PENG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Hao","family":"ZHAO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Tong","family":"DONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Xiao","family":"XU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Teng","family":"MA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yang","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jie","family":"ZHOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11138","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1016\/S0140-6736(21)00684-X","article-title":"The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030","volume":"397","author":"B Vogel","year":"2021","unstructured":"B Vogel. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. 2021, 397: 2385-2438.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000381472","article-title":"Sex differences in longevity and in responses to anti-aging interventions: a mini-review","volume":"62","author":"SN Austad","year":"2015","unstructured":"SN Austad. Sex differences in longevity and in responses to anti-aging interventions: a mini-review. 2015, 62: 40-46.","journal-title":"Gerontology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000491","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"EJ Benjamin. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. 2017, 135: e146-e603.","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"12E","DOI":"10.1016\/S0002-9149(02)02405-0","article-title":"Protective effects of estrogen on the cardiovascular system","volume":"89","author":"ME Mendelsohn","year":"2002","unstructured":"ME Mendelsohn. Protective effects of estrogen on the cardiovascular system. 2002, 89: 12E-17E.","journal-title":"Am J Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1161\/01.HYP.37.5.1199","article-title":"Gender differences in the regulation of blood pressure","volume":"37","author":"JF Reckelhoff","year":"2001","unstructured":"JF Reckelhoff. Gender differences in the regulation of blood pressure. 2001, 37: 1199-1208.","journal-title":"Hypertension"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/archinte.155.1.57","article-title":"Risk factors that attenuate the female coronary disease advantage","volume":"155","author":"WB Kannel","year":"1995","unstructured":"WB Kannel. Risk factors that attenuate the female coronary disease advantage. 1995, 155: 57-61.","journal-title":"Arch Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1080\/13697130802040077","article-title":"Estetrol: a unique steroid in human pregnancy","volume":"11","author":"CF Holinka","year":"2008","unstructured":"CF Holinka. Estetrol: a unique steroid in human pregnancy. 2008, 11: S1.","journal-title":"Climacteric"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pharmthera.2012.03.007","article-title":"Estrogen and the cardiovascular system","volume":"135","author":"AA Knowlton","year":"2012","unstructured":"AA Knowlton. Estrogen and the cardiovascular system. 2012, 135: 54-70.","journal-title":"Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/aogs.12771","article-title":"Physiology, production and action of progesterone","volume":"94","author":"S Taraborrelli","year":"2015","unstructured":"S Taraborrelli. Physiology, production and action of progesterone. 2015, 94: 8-16.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13293-017-0152-8","article-title":"The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy","volume":"8","author":"A Iorga","year":"2017","unstructured":"A Iorga. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. 2017, 8: 33.","journal-title":"Biol Sex Differ"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1067\/mjd.2001.117432","article-title":"Estrogen production and action","volume":"45","author":"LR Nelson","year":"2001","unstructured":"LR Nelson. Estrogen production and action. 2001, 45: S116-S124.","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.tem.2017.05.006","article-title":"Progesterone-mediated non-classical signaling","volume":"28","author":"D Garg","year":"2017","unstructured":"D Garg. Progesterone-mediated non-classical signaling. 2017, 28: 656-668.","journal-title":"Trends Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2478\/jtim-2023-0107","article-title":"Long-term blood pressure outcomes of laparoscopic adrenalectomy in trHTN patients","volume":"11","author":"Y Deng","year":"2021","unstructured":"Y Deng. Long-term blood pressure outcomes of laparoscopic adrenalectomy in trHTN patients. 2021, 11: 275-281.","journal-title":"J Transl Int Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"2019 Risk Factors Collaborators GBD","year":"2020","unstructured":"2019 Risk Factors Collaborators GBD. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. 2020, 396: 1223-1249.","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1146\/annurev-pharmtox-010716-104651","article-title":"GPER (GPR30): a nongenomic receptor (GPCR) for steroid hormones with implications for cardiovascular disease and cancer","volume":"57","author":"RD Feldman","year":"2017","unstructured":"RD Feldman. GPER (GPR30): a nongenomic receptor (GPCR) for steroid hormones with implications for cardiovascular disease and cancer. 2017, 57: 567-584.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/jtim-2022-0023","article-title":"Revising the hemodynamic criteria for pulmonary hypertension: a perspective from China","volume":"11","author":"C Xiong","year":"2023","unstructured":"C Xiong. Revising the hemodynamic criteria for pulmonary hypertension: a perspective from China. 2023, 11: 1-3.","journal-title":"J Transl Int Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"R159","DOI":"10.1152\/ajpregu.00256.2011","article-title":"The arterial depressor response to chronic low-dose angiotensin II infusion in female rats is estrogen dependent","volume":"302","author":"AK Sampson","year":"2012","unstructured":"AK Sampson. The arterial depressor response to chronic low-dose angiotensin II infusion in female rats is estrogen dependent. 2012, 302: R159-R165.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"R1908","DOI":"10.1152\/ajpregu.1997.273.6.R1908","article-title":"Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilator balance of RAS","volume":"273","author":"KB Brosnihan","year":"1997","unstructured":"KB Brosnihan. Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilator balance of RAS. 1997, 273: R1908-R1915.","journal-title":"Am J Physiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"R842","DOI":"10.1152\/ajpregu.00035.2003","article-title":"NO mediates effects of estrogen on central regulation of blood pressure in restrained, ovariectomized rats","volume":"285","author":"A Cherney","year":"2003","unstructured":"A Cherney. NO mediates effects of estrogen on central regulation of blood pressure in restrained, ovariectomized rats. 2003, 285: R842-R849.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/HYPERTENSIONAHA.107.091785","article-title":"Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring","volume":"50","author":"NB Ojeda","year":"2007","unstructured":"NB Ojeda. Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring. 2007, 50: 679-685.","journal-title":"Hypertension"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1590\/S0100-879X1999000400001","article-title":"Bi-directional actions of estrogen on the renin-angiotensin system","volume":"32","author":"KB Brosnihan","year":"1999","unstructured":"KB Brosnihan. Bi-directional actions of estrogen on the renin-angiotensin system. 1999, 32: 373-381.","journal-title":"Braz J Med Biol Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","article-title":"The protective effects of estrogen on the cardiovascular system","volume":"340","author":"ME Mendelsohn","year":"1999","unstructured":"ME Mendelsohn. The protective effects of estrogen on the cardiovascular system. 1999, 340: 1801-1811.","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nrneph.2017.189","article-title":"Sex-specific differences in hypertension and associated cardiovascular disease","volume":"14","author":"KMM Colafella","year":"2018","unstructured":"KMM Colafella. Sex-specific differences in hypertension and associated cardiovascular disease. 2018, 14: 185-201.","journal-title":"Nat Rev Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00002512-200724060-00002","article-title":"Drospirenone, a new progestogen, for postmenopausal women with hypertension","volume":"24","author":"M Mallareddy","year":"2007","unstructured":"M Mallareddy. Drospirenone, a new progestogen, for postmenopausal women with hypertension. 2007, 24: 453-466.","journal-title":"Drugs Aging"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/eurheartj\/ehv598","article-title":"Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes","volume":"37","author":"V Regitz-Zagrosek","year":"2016","unstructured":"V Regitz-Zagrosek. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. 2016, 37: 24-34.","journal-title":"Eur Heart J"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/MNH.0b013e328011d7f6","article-title":"Gonadal steroids, salt-sensitivity and renal function","volume":"16","author":"A Pechere-Bertschi","year":"2007","unstructured":"A Pechere-Bertschi. Gonadal steroids, salt-sensitivity and renal function. 2007, 16: 16-21.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref27","first-page":"495","article-title":"The role of sex hormones and sodium intake in postmenopausal hypertension","volume":"5","author":"T Tominaga","year":"1991","unstructured":"T Tominaga. The role of sex hormones and sodium intake in postmenopausal hypertension. 1991, 5: 495-500.","journal-title":"J Hum Hypertens"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1161\/HYPERTENSIONAHA.110.152975","article-title":"Postmenopausal hypertension: role of the renin-angiotensin system","volume":"56","author":"LL Yanes","year":"2010","unstructured":"LL Yanes. Postmenopausal hypertension: role of the renin-angiotensin system. 2010, 56: 359-363.","journal-title":"Hypertension"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1042\/cs0810515","article-title":"Changes in blood pressure during the normal menstrual cycle","volume":"81","author":"FP Dunne","year":"1991","unstructured":"FP Dunne. Changes in blood pressure during the normal menstrual cycle. 1991, 81: 515-518.","journal-title":"Clin Sci (Lond)"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2018.09.030","article-title":"Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: a prospective cohort study","volume":"278","author":"LM O\u2019Keeffe","year":"2018","unstructured":"LM O\u2019Keeffe. Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: a prospective cohort study. 2018, 278: 190-196.","journal-title":"Atherosclerosis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1161\/CIR.0000000000000351","article-title":"Acute myocardial infarction in women: a scientific statement from the American Heart Association","volume":"133","author":"LS Mehta","year":"2016","unstructured":"LS Mehta. Acute myocardial infarction in women: a scientific statement from the American Heart Association. 2016, 133: 916-947.","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0008-6363(01)00527-2","article-title":"Sex hormones and hypertension","volume":"53","author":"RK Dubey","year":"2002","unstructured":"RK Dubey. Sex hormones and hypertension. 2002, 53: 688-708.","journal-title":"Cardiovasc Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0895-7061(00)00284-3","article-title":"Hormone replacement therapy and 24-hour blood pressure profile of postmenopausal women","volume":"13","author":"A Butkevich","year":"2000","unstructured":"A Butkevich. Hormone replacement therapy and 24-hour blood pressure profile of postmenopausal women. 2000, 13: 1039-1041.","journal-title":"Am J Hypertens"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1067\/mob.2001.111246","article-title":"Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women","volume":"184","author":"B Cacciatore","year":"2001","unstructured":"B Cacciatore. Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women. 2001, 184: 904-909.","journal-title":"Am J Obstet Gynecol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00042192-200007010-00006","article-title":"Hormone replacement therapy reduces mean 24-hour blood pressure and its variability in postmenopausal women with treated hypertension","volume":"7","author":"B Szekacs","year":"2000","unstructured":"B Szekacs. Hormone replacement therapy reduces mean 24-hour blood pressure and its variability in postmenopausal women with treated hypertension. 2000, 7: 31-35.","journal-title":"Menopause"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.7326\/0003-4819-74-1-13","article-title":"Hypertension, oral contraceptive agents, and conjugated estrogens","volume":"74","author":"MG Crane","year":"1971","unstructured":"MG Crane. Hypertension, oral contraceptive agents, and conjugated estrogens. 1971, 74: 13-21.","journal-title":"Ann Intern Med"},{"key":"ref37","first-page":"2251","article-title":"Effect of natural oestrogens on blood pressure and weight in postmenopausal women","volume":"49","author":"M Notelovitz","year":"1975","unstructured":"M Notelovitz. Effect of natural oestrogens on blood pressure and weight in postmenopausal women. 1975, 49: 2251-2254.","journal-title":"S Afr Med J"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0378-5122(78)90003-8","article-title":"Effect of postmenopausal estrogen therapy on diastolic blood pressure and bodyweight","volume":"1","author":"WH Utian","year":"1978","unstructured":"WH Utian. Effect of postmenopausal estrogen therapy on diastolic blood pressure and bodyweight. 1978, 1: 3-8.","journal-title":"Maturitas"},{"key":"ref39","first-page":"491","article-title":"Hormone replacement therapy and blood pressure in hypertensive women","volume":"8","author":"GY Lip","year":"1994","unstructured":"GY Lip. Hormone replacement therapy and blood pressure in hypertensive women. 1994, 8: 491-494.","journal-title":"J Hum Hypertens"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1097\/00004872-199917100-00004","article-title":"A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease","volume":"17","author":"U Pripp","year":"1999","unstructured":"U Pripp. A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease. 1999, 17: 1379-1386.","journal-title":"J Hypertens"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/01.CIR.95.1.39","article-title":"Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women","volume":"95","author":"H Schunkert","year":"1997","unstructured":"H Schunkert. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. 1997, 95: 39-45.","journal-title":"Circulation"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s11906-006-0080-1","article-title":"Estrogen and hypertension","volume":"8","author":"MS Ashraf","year":"2006","unstructured":"MS Ashraf. Estrogen and hypertension. 2006, 8: 368-376.","journal-title":"Curr Hypertens Rep"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1097\/GME.0000000000001839","article-title":"Menopausal hormone therapy and risk of incident hypertension: role of the route of estrogen administration and progestogens in the E3N cohort","volume":"28","author":"AL Madika","year":"2021","unstructured":"AL Madika. Menopausal hormone therapy and risk of incident hypertension: role of the route of estrogen administration and progestogens in the E3N cohort. 2021, 28: 1204-1208.","journal-title":"Menopause"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1097\/GME.0000000000001828","article-title":"Hormone therapy formulation, dose, route of delivery, and risk of hypertension: findings from the Women\u2019s Health Initiative Observational Study (WHI-OS)","volume":"28","author":"RA Wild","year":"2021","unstructured":"RA Wild. Hormone therapy formulation, dose, route of delivery, and risk of hypertension: findings from the Women\u2019s Health Initiative Observational Study (WHI-OS). 2021, 28: 1108-1116.","journal-title":"Menopause"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.amjhyper.2005.10.006","article-title":"Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women","volume":"19","author":"J Ichikawa","year":"2006","unstructured":"J Ichikawa. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. 2006, 19: 744-749.","journal-title":"Am J Hypertens"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0029-7844(97)84258-5","article-title":"Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy","volume":"89","author":"AA Akkad","year":"1997","unstructured":"AA Akkad. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. 1997, 89: 97-103.","journal-title":"Obstet Gynecol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1161\/01.CIR.103.24.2903","article-title":"Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women","volume":"103","author":"W Vongpatanasin","year":"2001","unstructured":"W Vongpatanasin. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. 2001, 103: 2903-2908.","journal-title":"Circulation"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/GME.0b013e31829a64f9","article-title":"Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women\u2019s Health Initiative Observational Study","volume":"21","author":"CL Shufelt","year":"2014","unstructured":"CL Shufelt. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women\u2019s Health Initiative Observational Study. 2014, 21: 260-266.","journal-title":"Menopause"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"18s","DOI":"10.1002\/j.1552-4604.1995.tb04143.x","article-title":"Pharmacokinetic and pharmacologic variation between different estrogen products","volume":"35","author":"MB O\u2019Connell","year":"1995","unstructured":"MB O\u2019Connell. Pharmacokinetic and pharmacologic variation between different estrogen products. 1995, 35: 18s-24s.","journal-title":"J Clin Pharmacol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/HYPERTENSIONAHA.122.19938","article-title":"Association between the route of administration and formulation of estrogen therapy and hypertension risk in postmenopausal women: a prospective population-based study","volume":"80","author":"CZ Kalenga","year":"2023","unstructured":"CZ Kalenga. Association between the route of administration and formulation of estrogen therapy and hypertension risk in postmenopausal women: a prospective population-based study. 2023, 80: 1463-1473.","journal-title":"Hypertension"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1210\/jcem-73-4-837","article-title":"Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women","volume":"73","author":"W Oelkers","year":"1991","unstructured":"W Oelkers. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. 1991, 73: 837-842.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1210\/jcem.80.6.7775629","article-title":"Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism","volume":"80","author":"W Oelkers","year":"1995","unstructured":"W Oelkers. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. 1995, 80: 1816-1821.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.maturitas.2008.03.009","article-title":"Clinical experiences with drospirenone: from reproductive to postmenopausal years","volume":"60","author":"FR P\u00e9rez-L\u00f3pez","year":"2008","unstructured":"FR P\u00e9rez-L\u00f3pez. Clinical experiences with drospirenone: from reproductive to postmenopausal years. 2008, 60: 78-91.","journal-title":"Maturitas"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3109\/09513590009167683","article-title":"Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers","volume":"14","author":"W Oelkers","year":"2000","unstructured":"W Oelkers. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. 2000, 14: 204-213.","journal-title":"Gynecol Endocrinol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.maturitas.2006.07.009","article-title":"Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism","volume":"55","author":"S Palacios","year":"2006","unstructured":"S Palacios. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. 2006, 55: 297-307.","journal-title":"Maturitas"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.104.501502","article-title":"Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension","volume":"112","author":"WB White","year":"2005","unstructured":"WB White. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. 2005, 112: 1979-1984.","journal-title":"Circulation"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4103\/ijmr.IJMR_478_20","article-title":"Effects of continuous-combined oral drospirenone- estradiol on blood pressure, body weight & lipid profile in early menopausal women","volume":"154","author":"A \u0110ogo","year":"2021","unstructured":"A \u0110ogo. Effects of continuous-combined oral drospirenone- estradiol on blood pressure, body weight & lipid profile in early menopausal women. 2021, 154: 857-865.","journal-title":"Indian J Med Res"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e1003731","DOI":"10.1371\/journal.pmed.1003731","article-title":"Menopausal hormone therapy and women\u2019s health: an umbrella review","volume":"18","author":"GQ Zhang","year":"2021","unstructured":"GQ Zhang. Menopausal hormone therapy and women\u2019s health: an umbrella review. 2021, 18: e1003731.","journal-title":"PLoS Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"JE Rossouw. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. 2002, 288: 321-333.","journal-title":"JAMA"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"GL Anderson","year":"2004","unstructured":"GL Anderson. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. 2004, 291: 1701-1712.","journal-title":"JAMA"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ijgo.12892","article-title":"The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention","volume":"146","author":"LC Poon","year":"2019","unstructured":"LC Poon. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. 2019, 146: 390-391.","journal-title":"Int J Gynaecol Obstet"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(20)32335-7","article-title":"Pre-eclampsia","volume":"398","author":"LC Chappell","year":"2021","unstructured":"LC Chappell. Pre-eclampsia. 2021, 398: 341-354.","journal-title":"Lancet"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.earlhumdev.2016.09.007","article-title":"Preeclampsia; short and long-term consequences for mother and neonate","volume":"102","author":"A Bokslag","year":"2016","unstructured":"A Bokslag. Preeclampsia; short and long-term consequences for mother and neonate. 2016, 102: 47-50.","journal-title":"Early Hum Dev"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.2147\/DDDT.S304316","article-title":"Estrogen and preeclampsia: potential of estrogens as therapeutic agents in preeclampsia","volume":"15","author":"C Shu","year":"2021","unstructured":"C Shu. Estrogen and preeclampsia: potential of estrogens as therapeutic agents in preeclampsia. 2021, 15: 2543-2550.","journal-title":"Drug Des Devel Ther"},{"key":"ref65","first-page":"739","article-title":"[Study of estradiol on treatment of preclampsia in rat model]","volume":"40","author":"XY Wang","year":"2005","unstructured":"XY Wang. [Study of estradiol on treatment of preclampsia in rat model]. 2005, 40: 739-742.","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3892\/ijmm.2020.4465","article-title":"The effects of estradiol on inflammatory and endothelial dysfunction in rats with preeclampsia","volume":"45","author":"ZH Lin","year":"2020","unstructured":"ZH Lin. The effects of estradiol on inflammatory and endothelial dysfunction in rats with preeclampsia. 2020, 45: 825-835.","journal-title":"Int J Mol Med"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3390\/biom12030422","article-title":"Progesterone attenuates SIRT1-deficiency-mediated pre-eclampsia","volume":"12","author":"J Pei","year":"2022","unstructured":"J Pei. Progesterone attenuates SIRT1-deficiency-mediated pre-eclampsia. 2022, 12: 422.","journal-title":"Biomolecules"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1177\/09636897221145682","author":"","unstructured":"","journal-title":"null"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.preghy.2017.12.003","article-title":"The reduction in circulating levels of estrogen and progesterone in women with preeclampsia","volume":"11","author":"J Wan","year":"2018","unstructured":"J Wan. The reduction in circulating levels of estrogen and progesterone in women with preeclampsia. 2018, 11: 18-25.","journal-title":"Pregnancy Hypertens"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12958-020-0569-5","article-title":"Levels of sex steroid hormones and their receptors in women with preeclampsia","volume":"18","author":"KC Lan","year":"2020","unstructured":"KC Lan. Levels of sex steroid hormones and their receptors in women with preeclampsia. 2020, 18: 12.","journal-title":"Reprod Biol Endocrinol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/hr.2012.109","article-title":"Plasma level of hydroxysteroid (17-\u03b2) dehydrogenase 1 in the second trimester is an independent risk factor for predicting preeclampsia after adjusting for the effects of mean blood pressure, bilateral notching and plasma level of soluble fms-like tyrosine kinase 1\/placental growth factor ratio","volume":"35","author":"A Ohkuchi","year":"2012","unstructured":"A Ohkuchi. Plasma level of hydroxysteroid (17-\u03b2) dehydrogenase 1 in the second trimester is an independent risk factor for predicting preeclampsia after adjusting for the effects of mean blood pressure, bilateral notching and plasma level of soluble fms-like tyrosine kinase 1\/placental growth factor ratio. 2012, 35: 1152-1158.","journal-title":"Hypertens Res"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.placenta.2018.07.004","article-title":"Abnormal steroidogenesis and aromatase activity in preeclampsia","volume":"69","author":"N Berkane","year":"2018","unstructured":"N Berkane. Abnormal steroidogenesis and aromatase activity in preeclampsia. 2018, 69: 40-49.","journal-title":"Placenta"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.arcmed.2017.03.006","article-title":"Catechol-O-methyltransferase gene polymorphism (Val158Met) and development of pre-eclampsia","volume":"48","author":"A Taravati","year":"2017","unstructured":"A Taravati. Catechol-O-methyltransferase gene polymorphism (Val158Met) and development of pre-eclampsia. 2017, 48: 180-186.","journal-title":"Arch Med Res"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12958-021-00846-6","article-title":"Pregnancy-related complications and perinatal outcomes following progesterone supplementation before 20 weeks of pregnancy in spontaneously achieved singleton pregnancies: a systematic review and meta-analysis","volume":"19","author":"H Wu","year":"2021","unstructured":"H Wu. Pregnancy-related complications and perinatal outcomes following progesterone supplementation before 20 weeks of pregnancy in spontaneously achieved singleton pregnancies: a systematic review and meta-analysis. 2021, 19: 165.","journal-title":"Reprod Biol Endocrinol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.106.664979","article-title":"Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 nationwide French hospitals database","volume":"115","author":"C Milcent","year":"2007","unstructured":"C Milcent. Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 nationwide French hospitals database. 2007, 115: 833-839.","journal-title":"Circulation"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"E118","DOI":"10.1503\/cmaj.081197","article-title":"National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994\u20132004","volume":"180","author":"JV Tu","year":"2009","unstructured":"JV Tu. National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994\u20132004. 2009, 180: E118-E125.","journal-title":"CMAJ"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/MOL.0b013e3283613a94","article-title":"Cholesterol and atherosclerosis: modulation by oestrogen","volume":"24","author":"M Barton","year":"2013","unstructured":"M Barton. Cholesterol and atherosclerosis: modulation by oestrogen. 2013, 24: 214-220.","journal-title":"Curr Opin Lipidol"},{"key":"ref79","first-page":"45","article-title":"Estrogen related mechanisms of hypertension in menopausal women","volume":"255","author":"M Buleishvili","year":"2016","unstructured":"M Buleishvili. Estrogen related mechanisms of hypertension in menopausal women. 2016, 255: 45-51.","journal-title":"Georgian Med News"},{"key":"ref80","first-page":"247","article-title":"Estrogen markedly increases LDL-receptor activity in hypercholesterolemic patients","volume":"31","author":"T Inukai","year":"2000","unstructured":"T Inukai. Estrogen markedly increases LDL-receptor activity in hypercholesterolemic patients. 2000, 31: 247-261.","journal-title":"J Med"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1161\/01.ATV.17.9.1800","article-title":"Importance of estrogen receptors in hepatic LDL receptor regulation","volume":"17","author":"P Parini","year":"1997","unstructured":"P Parini. Importance of estrogen receptors in hepatic LDL receptor regulation. 1997, 17: 1800-1805.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0022-2275(20)30144-9","article-title":"Estrogen receptor-mediated repression of human hepatic lipase gene transcription","volume":"43","author":"DR Jones","year":"2002","unstructured":"DR Jones. Estrogen receptor-mediated repression of human hepatic lipase gene transcription. 2002, 43: 383-391.","journal-title":"J Lipid Res"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1161\/ATVBAHA.111.242461","article-title":"Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women","volume":"32","author":"L Persson","year":"2012","unstructured":"L Persson. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. 2012, 32: 810-814.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.2174\/0929867322666150608093607","article-title":"Vascular inflammation and atherosclerosis: the role of estrogen receptors","volume":"22","author":"E Kassi","year":"2015","unstructured":"E Kassi. Vascular inflammation and atherosclerosis: the role of estrogen receptors. 2015, 22: 2651-2665.","journal-title":"Curr Med Chem"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0021-9150(99)00315-9","article-title":"The effect of menopause on blood lipid and lipoprotein levels. The Icarus Study Group","volume":"147","author":"D de Aloysio","year":"1999","unstructured":"D de Aloysio. The effect of menopause on blood lipid and lipoprotein levels. The Icarus Study Group. 1999, 147: 147-153.","journal-title":"Atherosclerosis"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1210\/jc.2004-0744","article-title":"Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study","volume":"90","author":"S Mudali","year":"2005","unstructured":"S Mudali. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. 2005, 90: 1202-1209.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.10.009","author":"","unstructured":"","journal-title":"null"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/gme.0b013e3181dbdc30","article-title":"Serum lipid profile changes during the menopausal transition in Chinese women: a community-based cohort study","volume":"17","author":"JL Zhou","year":"2010","unstructured":"JL Zhou. Serum lipid profile changes during the menopausal transition in Chinese women: a community-based cohort study. 2010, 17: 997-1003.","journal-title":"Menopause"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1515\/CCLM.2002.076","article-title":"Hormone replacement therapy in postmenopausal women and its effects on plasma lipid levels","volume":"40","author":"LC Erberich","year":"2002","unstructured":"LC Erberich. Hormone replacement therapy in postmenopausal women and its effects on plasma lipid levels. 2002, 40: 446-451.","journal-title":"Clin Chem Lab Med"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S0015-0282(01)01699-5","article-title":"Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974\u20132000","volume":"75","author":"IF Godsland","year":"2001","unstructured":"IF Godsland. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974\u20132000. 2001, 75: 898-915.","journal-title":"Fertil Steril"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jama.288.1.58","article-title":"Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II)","volume":"288","author":"S Hulley","year":"2002","unstructured":"S Hulley. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II). 2002, 288: 58-66.","journal-title":"JAMA"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group","volume":"280","author":"S Hulley","year":"1998","unstructured":"S Hulley. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. 1998, 280: 605-613.","journal-title":"JAMA"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"JE Manson","year":"2003","unstructured":"JE Manson. Estrogen plus progestin and the risk of coronary heart disease. 2003, 349: 523-534.","journal-title":"N Engl J Med"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.fertnstert.2009.06.032","article-title":"Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women\u2019s Health Initiative era","volume":"92","author":"FR P\u00e9rez-L\u00f3pez","year":"2009","unstructured":"FR P\u00e9rez-L\u00f3pez. Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women\u2019s Health Initiative era. 2009, 92: 1171-1186.","journal-title":"Fertil Steril"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/gme.0b013e3182843aad","article-title":"Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future","volume":"20","author":"TB Clarkson","year":"2013","unstructured":"TB Clarkson. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. 2013, 20: 342-353.","journal-title":"Menopause"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1172\/JCI117619","article-title":"Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques","volume":"94","author":"ZS Galis","year":"1994","unstructured":"ZS Galis. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. 1994, 94: 2493-2503.","journal-title":"J Clin Invest"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJM199109123251102","article-title":"Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses\u2019 health study","volume":"325","author":"MJ Stampfer","year":"1991","unstructured":"MJ Stampfer. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses\u2019 health study. 1991, 325: 756-762.","journal-title":"N Engl J Med"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials","volume":"310","author":"JE Manson","year":"2013","unstructured":"JE Manson. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials. 2013, 310: 1353-1368.","journal-title":"JAMA"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"JE Rossouw","year":"2007","unstructured":"JE Rossouw. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. 2007, 297: 1465-1477.","journal-title":"JAMA"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1505241","article-title":"Vascular effects of early versus late postmenopausal treatment with estradiol","volume":"374","author":"HN Hodis","year":"2016","unstructured":"HN Hodis. Vascular effects of early versus late postmenopausal treatment with estradiol. 2016, 374: 1221-1231.","journal-title":"N Engl J Med"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"2016 IMS recommendations on women\u2019s midlife health and menopause hormone therapy","volume":"19","author":"RJ Baber","year":"2016","unstructured":"RJ Baber. 2016 IMS recommendations on women\u2019s midlife health and menopause hormone therapy. 2016, 19: 109-150.","journal-title":"Climacteric"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032566","author":"","unstructured":"","journal-title":"null"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1388-9842(02)00034-X","article-title":"Prevalence of chronic heart failure in Southwestern Europe: the EPICA study","volume":"4","author":"F Ceia","year":"2002","unstructured":"F Ceia. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. 2002, 4: 531-539.","journal-title":"Eur J Heart Fail"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1093\/eurheartj\/ehad619","article-title":"Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry","volume":"44","author":"A Cai","year":"2023","unstructured":"A Cai. Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry. 2023, 44: 4715-4718.","journal-title":"Eur Heart J"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1161\/01.RES.0000046018.23605.3E","article-title":"Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygenase activation","volume":"91","author":"A Alvarez","year":"2002","unstructured":"A Alvarez. Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygenase activation. 2002, 91: 1142-1150.","journal-title":"Circ Res"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"26339","DOI":"10.1074\/jbc.M414409200","article-title":"Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1","volume":"280","author":"A Pedram","year":"2005","unstructured":"A Pedram. Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. 2005, 280: 26339-26348.","journal-title":"J Biol Chem"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1210\/en.2008-0133","article-title":"Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin","volume":"149","author":"A Pedram","year":"2008","unstructured":"A Pedram. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. 2008, 149: 3361-3369.","journal-title":"Endocrinology"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1210\/jcem-70-2-349","article-title":"The influence of gender, age, and the menstrual cycle on plasma atrial natriuretic peptide","volume":"70","author":"BA Clark","year":"1990","unstructured":"BA Clark. The influence of gender, age, and the menstrual cycle on plasma atrial natriuretic peptide. 1990, 70: 349-352.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jacc.2011.03.042","article-title":"Influence of sex and hormone status on circulating natriuretic peptides","volume":"58","author":"CS Lam","year":"2011","unstructured":"CS Lam. Influence of sex and hormone status on circulating natriuretic peptides. 2011, 58: 618-626.","journal-title":"J Am Coll Cardiol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0378-5122(03)00279-2","article-title":"Effects of estrogen replacement therapy on natriuretic peptides and blood pressure","volume":"47","author":"AH Karjalainen","year":"2004","unstructured":"AH Karjalainen. Effects of estrogen replacement therapy on natriuretic peptides and blood pressure. 2004, 47: 201-208.","journal-title":"Maturitas"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"SD Solomon","year":"2019","unstructured":"SD Solomon. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. 2019, 381: 1609-1620.","journal-title":"N Engl J Med"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.927764","author":"","unstructured":"","journal-title":"null"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/cvr\/cvy185","article-title":"Sex-specific regulation of collagen I and III expression by 17\u03b2-estradiol in cardiac fibroblasts: role of estrogen receptors","volume":"115","author":"E Dworatzek","year":"2019","unstructured":"E Dworatzek. Sex-specific regulation of collagen I and III expression by 17\u03b2-estradiol in cardiac fibroblasts: role of estrogen receptors. 2019, 115: 315-327.","journal-title":"Cardiovasc Res"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1161\/CIRCULATIONAHA.106.638569","article-title":"Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction","volume":"115","author":"R Martos","year":"2007","unstructured":"R Martos. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. 2007, 115: 888-895.","journal-title":"Circulation"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/prca.201500031","article-title":"Effects of aging on cardiac extracellular matrix in men and women","volume":"10","author":"E Dworatzek","year":"2016","unstructured":"E Dworatzek. Effects of aging on cardiac extracellular matrix in men and women. 2016, 10: 84-91.","journal-title":"Proteomics Clin Appl"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4103\/0976-7800.118990","article-title":"The role of oxidative stress in menopause","volume":"4","author":"SB Doshi","year":"2013","unstructured":"SB Doshi. The role of oxidative stress in menopause. 2013, 4: 140-146.","journal-title":"J Midlife Health"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1161\/CIRCULATIONAHA.109.883777","article-title":"Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction","volume":"121","author":"GA Silberman","year":"2010","unstructured":"GA Silberman. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. 2010, 121: 519-528.","journal-title":"Circulation"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1210\/jcem.85.4.6530","article-title":"Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity","volume":"85","author":"NG Majmudar","year":"2000","unstructured":"NG Majmudar. Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity. 2000, 85: 1577-1583.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jacc.2019.12.049","article-title":"Menopause-related estrogen decrease and the pathogenesis of HFpEF: JACC review topic of the week","volume":"75","author":"AR Sabbatini","year":"2020","unstructured":"AR Sabbatini. Menopause-related estrogen decrease and the pathogenesis of HFpEF: JACC review topic of the week. 2020, 75: 1074-1082.","journal-title":"J Am Coll Cardiol"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.105.541078","article-title":"Age- and gender-related ventricular-vascular stiffening: a community-based study","volume":"112","author":"MM Redfield","year":"2005","unstructured":"MM Redfield. Age- and gender-related ventricular-vascular stiffening: a community-based study. 2005, 112: 2254-2262.","journal-title":"Circulation"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/00045391-200303000-00005","article-title":"Left ventricular diastolic function assessment by tissue Doppler echocardiography in relation to hormonal replacement therapy in postmenopausal women with diastolic dysfunction","volume":"10","author":"M G\u00f6k\u00e7e","year":"2003","unstructured":"M G\u00f6k\u00e7e. Left ventricular diastolic function assessment by tissue Doppler echocardiography in relation to hormonal replacement therapy in postmenopausal women with diastolic dysfunction. 2003, 10: 104-111.","journal-title":"Am J Ther"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/0002-9149(93)90525-H","article-title":"Left ventricular diastolic function by Doppler echocardiography in relation to hormonal replacement therapy in healthy postmenopausal women","volume":"71","author":"S Voutilainen","year":"1993","unstructured":"S Voutilainen. Left ventricular diastolic function by Doppler echocardiography in relation to hormonal replacement therapy in healthy postmenopausal women. 1993, 71: 614-617.","journal-title":"Am J Cardiol"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S0002-9149(99)00029-6","article-title":"Effect of hormone replacement therapy on left ventricular hypertrophy","volume":"83","author":"WK Lim","year":"1999","unstructured":"WK Lim. Effect of hormone replacement therapy on left ventricular hypertrophy. 1999, 83: 1132-1134,a1139.","journal-title":"Am J Cardiol"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/00004872-200102000-00014","article-title":"Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women","volume":"19","author":"KC Light","year":"2001","unstructured":"KC Light. Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. 2001, 19: 269-278.","journal-title":"J Hypertens"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/gme.0b013e31827461e0","article-title":"Differential effects of estradiol on carotid artery inflammation when administered early versus late after surgical menopause","volume":"20","author":"A Sophonsritsuk","year":"2013","unstructured":"A Sophonsritsuk. Differential effects of estradiol on carotid artery inflammation when administered early versus late after surgical menopause. 2013, 20: 540-547.","journal-title":"Menopause"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"e009769","DOI":"10.1161\/JAHA.118.009769","article-title":"Estradiol treatment initiated early after ovariectomy regulates myocardial gene expression and inhibits diastolic dysfunction in female cynomolgus monkeys: potential roles for calcium homeostasis and extracellular matrix remodeling","volume":"7","author":"KT Michalson","year":"2018","unstructured":"KT Michalson. Estradiol treatment initiated early after ovariectomy regulates myocardial gene expression and inhibits diastolic dysfunction in female cynomolgus monkeys: potential roles for calcium homeostasis and extracellular matrix remodeling. 2018, 7: e009769.","journal-title":"J Am Heart Assoc"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1161\/STROKEAHA.121.037305","article-title":"Risks of stroke and heart disease following hysterectomy and oophorectomy in Chinese premenopausal women","volume":"53","author":"MHF Poorthuis","year":"2022","unstructured":"MHF Poorthuis. Risks of stroke and heart disease following hysterectomy and oophorectomy in Chinese premenopausal women. 2022, 53: 3064-3071.","journal-title":"Stroke"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"e006713","DOI":"10.1161\/JAHA.117.006713","article-title":"Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of cardiovascular disease in women","volume":"6","author":"SH Ley","year":"2017","unstructured":"SH Ley. Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of cardiovascular disease in women. 2017, 6: e006713.","journal-title":"J Am Heart Assoc"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.2019.19191","article-title":"Association of premature natural and surgical menopause with incident cardiovascular disease","volume":"322","author":"MC Honigberg","year":"2019","unstructured":"MC Honigberg. Association of premature natural and surgical menopause with incident cardiovascular disease. 2019, 322: 2411-2421.","journal-title":"JAMA"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/GME.0000000000001729","article-title":"Early and surgical menopause associated with higher Framingham Risk Scores for cardiovascular disease in the Canadian Longitudinal Study on Aging","volume":"28","author":"MA Price","year":"2021","unstructured":"MA Price. Early and surgical menopause associated with higher Framingham Risk Scores for cardiovascular disease in the Canadian Longitudinal Study on Aging. 2021, 28: 484-490.","journal-title":"Menopause"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline","volume":"100","author":"CA Stuenkel","year":"2015","unstructured":"CA Stuenkel. Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline. 2015, 100: 3975-4011.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamainternmed.2016.2761","article-title":"Diagnosis and management of menopause: the National Institute of Health and Care Excellence (NICE) Guideline","volume":"176","author":"MA Lumsden","year":"2016","unstructured":"MA Lumsden. Diagnosis and management of menopause: the National Institute of Health and Care Excellence (NICE) Guideline. 2016, 176: 1205-1206.","journal-title":"JAMA Intern Med"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S2213-8587(22)00285-6","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society: no news is good news","volume":"10","author":"RE Nappi","year":"2022","unstructured":"RE Nappi. The 2022 hormone therapy position statement of the North American Menopause Society: no news is good news. 2022, 10: 832-834.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab766","author":"","unstructured":"","journal-title":"null"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMcp2116488","article-title":"Primary ovarian insufficiency","volume":"388","author":"CA Stuenkel","year":"2023","unstructured":"CA Stuenkel. Primary ovarian insufficiency. 2023, 388: 154-163.","journal-title":"N Engl J Med"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1210\/jc.2009-1789","article-title":"Early age at menarche associated with cardiovascular disease and mortality","volume":"94","author":"R Lakshman","year":"2009","unstructured":"R Lakshman. Early age at menarche associated with cardiovascular disease and mortality. 2009, 94: 4953-4960.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/pubmed\/fdx118","article-title":"Early menarche and blood pressure in adulthood: systematic review and meta-analysis","volume":"40","author":"S Bubach","year":"2018","unstructured":"S Bubach. Early menarche and blood pressure in adulthood: systematic review and meta-analysis. 2018, 40: 476-484.","journal-title":"J Public Health (Oxf)"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1136\/heartjnl-2017-312289","article-title":"Women\u2019s reproductive factors and incident cardiovascular disease in the UK Biobank","volume":"104","author":"SA Peters","year":"2018","unstructured":"SA Peters. Women\u2019s reproductive factors and incident cardiovascular disease in the UK Biobank. 2018, 104: 1069-1075.","journal-title":"Heart"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.114.010070","article-title":"Age at menarche and risk of coronary heart and other vascular diseases in a large UK cohort","volume":"131","author":"D Canoy","year":"2015","unstructured":"D Canoy. Age at menarche and risk of coronary heart and other vascular diseases in a large UK cohort. 2015, 131: 237-244.","journal-title":"Circulation"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","article-title":"Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data","volume":"4","author":"D Zhu","year":"2019","unstructured":"D Zhu. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. 2019, 4: e553-e564.","journal-title":"Lancet Public Health"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"Cd011054","DOI":"10.1002\/14651858.CD011054","article-title":"Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke","volume":"2015","author":"RE Roach","year":"2015","unstructured":"RE Roach. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. 2015, 2015: Cd011054.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(96)91334-3","article-title":"Risk of acute myocardial infarction and low-dose combined oral contraceptive","volume":"347","author":"H Jick","year":"1996","unstructured":"H Jick. Risk of acute myocardial infarction and low-dose combined oral contraceptive. 1996, 347: 627-628.","journal-title":"Lancet"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/jim-2018-000750","article-title":"Associations of hormonal contraceptives and infertility medications on the risk of venous thromboembolism, ischemic stroke, and cardiovascular disease in women","volume":"67","author":"SQ Ge","year":"2019","unstructured":"SQ Ge. Associations of hormonal contraceptives and infertility medications on the risk of venous thromboembolism, ischemic stroke, and cardiovascular disease in women. 2019, 67: 729-735.","journal-title":"J Investig Med"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"i2002","DOI":"10.1136\/bmj.i2002","article-title":"Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study","volume":"353","author":"A Weill","year":"2016","unstructured":"A Weill. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. 2016, 353: i2002.","journal-title":"BMJ"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"c927","DOI":"10.1136\/bmj.c927","article-title":"Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners\u2019 Oral Contraception Study","volume":"340","author":"PC Hannaford","year":"2010","unstructured":"PC Hannaford. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners\u2019 Oral Contraception Study. 2010, 340: c927.","journal-title":"BMJ"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.contraception.2010.04.006","article-title":"Factors affecting mortality in a large cohort study with special reference to oral contraceptive use","volume":"82","author":"M Vessey","year":"2010","unstructured":"M Vessey. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. 2010, 82: 221-229.","journal-title":"Contraception"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","article-title":"Thrombotic stroke and myocardial infarction with hormonal contraception","volume":"366","author":"\u00d8 Lidegaard","year":"2012","unstructured":"\u00d8 Lidegaard. Thrombotic stroke and myocardial infarction with hormonal contraception. 2012, 366: 2257-2266.","journal-title":"N Engl J Med"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1161\/STROKEAHA.121.038659","article-title":"Oral contraceptives, hormone replacement therapy, and stroke risk","volume":"53","author":"T Johansson","year":"2022","unstructured":"T Johansson. Oral contraceptives, hormone replacement therapy, and stroke risk. 2022, 53: 3107-3115.","journal-title":"Stroke"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"e030105","DOI":"10.1161\/JAHA.123.030105","article-title":"Associations of oral contraceptive use with cardiovascular disease and all-cause death: evidence from the UK Biobank cohort study","volume":"12","author":"W Dou","year":"2023","unstructured":"W Dou. Associations of oral contraceptive use with cardiovascular disease and all-cause death: evidence from the UK Biobank cohort study. 2023, 12: e030105.","journal-title":"J Am Heart Assoc"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jacc.2020.05.084","article-title":"Spontaneous coronary artery dissection: JACC State-of-the-Art Review","volume":"76","author":"SN Hayes","year":"2020","unstructured":"SN Hayes. Spontaneous coronary artery dissection: JACC State-of-the-Art Review. 2020, 76: 961-984.","journal-title":"J Am Coll Cardiol"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1056\/NEJMra2001524","article-title":"Spontaneous coronary artery dissection","volume":"383","author":"ESH Kim","year":"2020","unstructured":"ESH Kim. Spontaneous coronary artery dissection. 2020, 383: 2358-2370.","journal-title":"N Engl J Med"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"e022746","DOI":"10.1161\/JAHA.121.022746","article-title":"Breastfeeding is associated with a reduced maternal cardiovascular risk: systematic review and meta-analysis involving data from 8 studies and 1, 192, 700 parous women","volume":"11","author":"L Tschiderer","year":"2022","unstructured":"L Tschiderer. Breastfeeding is associated with a reduced maternal cardiovascular risk: systematic review and meta-analysis involving data from 8 studies and 1, 192, 700 parous women. 2022, 11: e022746.","journal-title":"J Am Heart Assoc"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2826.2011.02235.x","article-title":"Oxytocin revisited: its role in cardiovascular regulation","volume":"24","author":"J Gutkowska","year":"2012","unstructured":"J Gutkowska. Oxytocin revisited: its role in cardiovascular regulation. 2012, 24: 599-608.","journal-title":"J Neuroendocrinol"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"170089","DOI":"10.1016\/j.peptides.2019.05.001","article-title":"Oxytocin: potential to mitigate cardiovascular risk","volume":"117","author":"AB Reiss","year":"2019","unstructured":"AB Reiss. Oxytocin: potential to mitigate cardiovascular risk. 2019, 117: 170089.","journal-title":"Peptides"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"e902","DOI":"10.1161\/CIR.0000000000000961","article-title":"Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association","volume":"143","author":"NI Parikh","year":"2021","unstructured":"NI Parikh. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. 2021, 143: e902-e916.","journal-title":"Circulation"}],"container-title":["Journal of Geriatric Cardiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T08:41:49Z","timestamp":1720514509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciopen.com\/article\/10.26599\/1671-5411.2024.06.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":154,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.26599\/1671-5411.2024.06.003","relation":{},"ISSN":["1671-5411"],"issn-type":[{"value":"1671-5411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}